残留肿瘤体积指导前庭神经鞘瘤术后治疗策略及挽救性放疗需求
该单中心回顾性研究纳入1119例前庭神经鞘瘤患者,其中38例(3.4%)接受次全切除术,15例(39.5%)后续需辅助放疗。接受辅助放疗者平均残留体积为37.53±12.33%,显著高于仅观察者的15.26±3.54%(p<0.001)。多变量分析显示残留体积百分比独立预测辅助放疗需求(AOR 1.28,CI 1.06-2.29,p=0.002)。
要点
- 次全切除适用于部分复杂前庭神经鞘瘤病例
- 残留体积≥20.6%可能增加进展风险及辅助放疗需求
- 术后2-3年密切影像随访是必要的
核心结论
- 次全切除在部分复杂前庭神经鞘瘤病例中可行,残留体积百分比独立预测辅助放疗需求。
研究设计与样本
- 单中心回顾性综述(2009-2019年),纳入1119例前庭神经鞘瘤患者中38例接受次全切除且资料完整的病例。
主要发现
- 38例次全切除患者中15例(39.5%)需辅助放疗。
- 仅次全切除组平均残留体积15.26±3.54%,次全切除+辅助放疗组37.53±12.33%(p<0.001)。
- 需辅助放疗的最小残留体积为23.4%,未需辅助放疗的最大残留体积为20.6%。
- 辅助放疗患者中位无进展生存期为29.67个月。
- 多变量分析中残留体积百分比独立预测辅助放疗需求(AOR 1.28,CI 1.06-2.29,p=0.002)。
关键数值与推荐
- 残留体积≥20.6%可能增加进展风险并需辅助放疗。
- 术后2-3年密切 surveillance 是必要的。
临床怎么用
- 对于选择次全切除的复杂前庭神经鞘瘤病例,应量化术后残留体积以评估辅助放疗风险。
- 残留体积≥20.6%者建议加强术后2-3年影像随访,必要时及时启动辅助放疗。
局限性
- 单中心回顾性设计,次全切除样本量较小(38例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Vestibular schwannomas (VS) are slow-growing tumors of the vestibular nerve. Gross total resection (GTR) is recommended for large tumors (> 4 cm), brainstem compression, cranial neuropathy, and hydrocephalus. In select complex cases at our high-volume skull base center, subtotal resection (STR) is pursued for various clinical factors. These patients may require adjuvant radiotherapy (ART) if residual tumor progresses. We sought to evaluate tumor control following STR of VS and identify risk factors of future ART need. METHODS: A single-center retrospective review (2009-2019) identified patients with VS with complete data who underwent STR without prior treatment. Tumor volumes were extracted from contrast-enhanced T1-weighted volumetric MRI by semi-automated segmentation using 3D Slicer. Clinical and procedural data, including House-Brackmann scores at discharge and 90-day follow-up, were reviewed. Postoperative tumor volumes and progression-free survival (PFS) were calculated. Multivariate logistic regression assessed risk factors for ART. RESULTS: Among 1119 VS patients, 38 (3.4%) patients underwent STR. Of the STR patients, 15 (39.5%) required ART. Preoperative volumes did not differ significantly. In STR-alone patients, the average residual volume was 15.26 ± 3.54%, while in STR + ART patients the average residual volume was 37.53 ± 12.33% (p < 0.001). The smallest residual requiring ART was 23.4%, while the largest residual not requiring ART was 20.6%. Median PFS among ART patients was 29.67 months. On multivariate analysis, percent residual volume independently predicted ART need (AOR 1.28, CI 1.06-2.29, p = 0.002). CONCLUSION: STR is viable in select complex VS cases. Residual VS volume ≥ 20.6% may confer increased risk of progression and necessitate ART. Close postoperative surveillance over 2-3 years is warranted.
引用
- Unterberger A, Devarajan A, Zhang J, et al. Residual tumor volume guides post-surgical treatment paradigm and need for salvage radiotherapy in vestibular schwannoma management. J Neurooncol. 2026. PMID: 42105194. doi:10.1007/s11060-026-05603-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。